HC Wainwright Reaffirms Buy Rating for Gossamer Bio (NASDAQ:GOSS)

HC Wainwright reaffirmed their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Gossamer Bio’s Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.56) EPS, FY2027 earnings at ($0.04) EPS, FY2028 earnings at $0.24 EPS and FY2029 earnings at $0.55 EPS.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $4.00 price target on shares of Gossamer Bio in a report on Friday, March 14th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Gossamer Bio has a consensus rating of “Buy” and an average price target of $9.20.

Gossamer Bio Stock Performance

Gossamer Bio stock opened at $1.35 on Tuesday. Gossamer Bio has a 1-year low of $0.50 and a 1-year high of $1.55. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The firm has a market capitalization of $306.75 million, a PE ratio of -4.22 and a beta of 1.86. The firm’s 50 day simple moving average is $1.16 and its 200 day simple moving average is $0.98.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). The firm had revenue of $9.38 million during the quarter, compared to the consensus estimate of $7.02 million. As a group, analysts expect that Gossamer Bio will post -0.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GOSS. Octagon Capital Advisors LP raised its position in Gossamer Bio by 99.7% during the fourth quarter. Octagon Capital Advisors LP now owns 18,350,000 shares of the company’s stock valued at $16,599,000 after purchasing an additional 9,162,117 shares in the last quarter. Alyeska Investment Group L.P. raised its holdings in shares of Gossamer Bio by 52.7% during the 4th quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company’s stock valued at $7,968,000 after buying an additional 3,041,058 shares in the last quarter. Monaco Asset Management SAM raised its holdings in shares of Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after buying an additional 1,520,721 shares in the last quarter. Allostery Investments LP bought a new stake in Gossamer Bio in the 4th quarter worth approximately $555,000. Finally, Silverarc Capital Management LLC boosted its stake in Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company’s stock worth $5,583,000 after buying an additional 526,495 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.